Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis

被引：41

作者：

Alunno, Alessia ^{[1
]}

Carubbi, Francesco ^{[2
]}

Cafaro, Giacomo ^{[1
]}

Pucci, Giacomo ^{[1
,3
]}

Battista, Francesca ^{[1
,3
]}

Bartoloni, Elena ^{[1
]}

Giacomelli, Roberto ^{[2
]}

Schillaci, Giuseppe ^{[1
,3
]}

Gerli, Roberto ^{[1
]}

机构：

[1] Univ Perugia, Dept Med, I-06100 Perugia, Italy

[2] Univ Aquila, Rheumatol Unit, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy

[3] Terni Univ Hosp, Unit Internal Med, Terni, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2015年 / 15卷 / 12期

关键词：

IL-17; IL-23; psoriasis; psoriatic arthritis; COLLAGEN-INDUCED ARTHRITIS; TO-SEVERE PSORIASIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; CHRONIC PLAQUE PSORIASIS; HYPER-IGE SYNDROME; DOUBLE-BLIND; TH17; CELLS; EPIDERMAL HYPERPLASIA; RHEUMATOID-ARTHRITIS; FUNCTIONAL-ROLE;

D O I：

10.1517/14712598.2015.1084284

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Introduction: A growing amount of data supporting the pathogenic role of the IL-23/IL-17 axis in inflammatory/autoimmune disorders has provided the rationale to target the system for therapeutic purpose. Several compounds have been and are currently under intense investigation in psoriasis and psoriatic arthritis (PsA) yielding impressive results.Areas covered: In this review article, we provide an overview of currently available data on the IL-23/IL-17 system as a target for treatment for psoriasis and PsA. We searched MEDLINE for articles on drug therapy for psoriasis and PsA published between 1 January 2010 and 31 May 2015. One of these agents, ustekinumab, has been recently approved for the treatment of psoriasis and PsA, and a number of IL-23/IL-17-targeted compounds under investigation in these diseases.Expert opinion: As our knowledge of the role of the IL-23/IL-17 axis in the pathogenesis of psoriasis and PsA deepens, it enables the development of more targeted therapies in the management of these conditions. Early data on IL-23/IL-17 targeting drugs appear promising, although incomplete. Given the key role IL-23/IL-17 in host defence, the safety profile of targeted drugs should be thoroughly assessed in future studies.

引用

页码：1727 / 1737

页数：11

共 74 条

[1]

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J].